Formosa Laboratories Inc (4746) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Formosa Laboratories Inc (4746) has a cash flow conversion efficiency ratio of 0.018x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$156.90 Million ≈ $4.94 Million USD) by net assets (NT$8.68 Billion ≈ $273.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Formosa Laboratories Inc market capitalisation for the company's overall valuation and market capitalisation.
Formosa Laboratories Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Formosa Laboratories Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Formosa Laboratories Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Formosa Laboratories Inc ranked by their cash flow conversion efficiency. Explore 4746 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amaero Ltd
AU:3DA
|
-0.190x |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
0.699x |
|
Neto M.E Holdings Ltd
TA:NTO
|
-0.105x |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
-0.166x |
|
SFP Tech Holdings Bhd
KLSE:0251
|
0.021x |
|
Home Center Holdings Co.Ltd
KQ:060560
|
0.000x |
|
Readly International AB
ST:READ
|
0.372x |
|
Draganfly Inc
NASDAQ:DPRO
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Formosa Laboratories Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Formosa Laboratories Inc from 2009 to 2025. View 4746 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$8.67 Billion ≈ $273.16 Million |
NT$1.32 Billion ≈ $41.44 Million |
0.152x | +80.59% |
| 2024-12-31 | NT$8.65 Billion ≈ $272.42 Million |
NT$726.33 Million ≈ $22.88 Million |
0.084x | -16.57% |
| 2023-12-31 | NT$8.21 Billion ≈ $258.67 Million |
NT$826.60 Million ≈ $26.04 Million |
0.101x | +22.06% |
| 2022-12-31 | NT$7.80 Billion ≈ $245.63 Million |
NT$643.09 Million ≈ $20.26 Million |
0.082x | +101.53% |
| 2021-12-31 | NT$7.60 Billion ≈ $239.51 Million |
NT$311.16 Million ≈ $9.80 Million |
0.041x | -54.45% |
| 2020-12-31 | NT$5.29 Billion ≈ $166.53 Million |
NT$475.00 Million ≈ $14.97 Million |
0.090x | +38.16% |
| 2019-12-31 | NT$4.46 Billion ≈ $140.43 Million |
NT$289.92 Million ≈ $9.13 Million |
0.065x | +466.48% |
| 2018-12-31 | NT$4.56 Billion ≈ $143.60 Million |
NT$-80.89 Million ≈ $-2.55 Million |
-0.018x | -118.41% |
| 2017-12-31 | NT$4.10 Billion ≈ $129.20 Million |
NT$395.42 Million ≈ $12.46 Million |
0.096x | -64.36% |
| 2016-12-31 | NT$4.10 Billion ≈ $129.29 Million |
NT$1.11 Billion ≈ $34.97 Million |
0.271x | +267.07% |
| 2015-12-31 | NT$3.46 Billion ≈ $109.08 Million |
NT$255.15 Million ≈ $8.04 Million |
0.074x | -20.23% |
| 2014-12-31 | NT$3.04 Billion ≈ $95.63 Million |
NT$280.41 Million ≈ $8.83 Million |
0.092x | +620.58% |
| 2013-12-31 | NT$2.52 Billion ≈ $79.26 Million |
NT$32.25 Million ≈ $1.02 Million |
0.013x | -87.46% |
| 2012-12-31 | NT$1.67 Billion ≈ $52.75 Million |
NT$171.13 Million ≈ $5.39 Million |
0.102x | +1810.84% |
| 2011-12-31 | NT$1.88 Billion ≈ $59.23 Million |
NT$-11.23 Million ≈ $-353.84K |
-0.006x | -108.35% |
| 2010-12-31 | NT$1.39 Billion ≈ $43.90 Million |
NT$99.67 Million ≈ $3.14 Million |
0.072x | -79.01% |
| 2009-12-31 | NT$1.33 Billion ≈ $41.98 Million |
NT$454.22 Million ≈ $14.31 Million |
0.341x | -- |
About Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomo… Read more